Lupin Sues Paddock Over Generic Antara

Law360, New York (February 3, 2011, 1:38 PM EST) -- Lupin Atlantis Holdings SA has hit Paddock Laboratories Inc. with a patent infringement suit over the defendant's plans to introduce a generic version of cholesterol-lowering drug Antara.

The suit, filed Tuesday in the U.S. District Court for the District of Minnesota, claims that the abbreviated new drug application Paddock holds for its generic version infringes a single patent for Antara.

According to the suit, Lupin received a letter from Paddock in December about its plans, in which Paddock alleged that Lupin's patent is not valid and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.